# Aarti Pharmalabs Ltd (AARTIPHARM)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹713.1
Day Change: +1.36%
52W High: ₹971
52W Low: ₹585
Market Cap: ₹6,358 Cr

## Valuation
P/E: 29.77
P/B: 3.11
EPS: ₹23.56
Book Value: ₹225.7
Dividend Yield: 0.56%

## Returns
1Y Return: -6.28%

## Profitability
ROE: 0%
ROCE: 21.17%
Debt/Equity: 0.33
Revenue Growth: -19.6%
Profit Growth: -35.2%
EBITDA Margin: 22.32%
Operating Margin: 17.05%

## About
Aarti Pharmalabs Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Aarti Pharmalabs Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Update on board meeting
- Quarterly Report: Board Meeting Intimation for Approval Of The Audited Financial Results For The Quarter And Financial Year Ended March 31, 2026 And Recommendation Of Final Dividend, If Any.
- BSE Filing: Update on board meeting

## Access
Current tier: anonymous
More history: Register free to see 1 more year.

## Data Freshness
Quote Updated: 2026-05-24T20:00:00.754Z
Price History Updated: 2026-05-17T21:23:44.852Z
Latest Price History Date: 2026-05-17
Technicals Updated: 2026-05-17T21:23:44.852Z
Quant Updated: 2026-05-17T21:23:44.852Z
Sentiment Updated: 2026-05-17T21:23:44.852Z
Financials Status: current
Financials Updated: 2026-05-18T12:31:06.649Z
Financials Last Attempt: 2026-05-18T12:31:06.649Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2023)
Revenue: ₹1200 Cr
Operating Profit: ₹207 Cr (OPM 17%)
Net Profit: ₹122 Cr
Tax: ₹155 Cr

## Annual P&L History
Mar 2023: Rev ₹1200Cr | PAT ₹122Cr | OPM 17%
Mar 2024: Rev ₹1945Cr | PAT ₹193Cr | OPM 18%
Mar 2025: Rev ₹1853Cr | PAT ₹217Cr | OPM 21%

## Balance Sheet (Mar 2023)
Total Assets: ₹2040 Cr
Total Liabilities: ₹2040 Cr
Borrowings: ₹341 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Hetal Gogri Gala, Vice Chairperson & MD
- Narendra Jagannath Salvi, MD & Director
- Piyush P. Lakhani, Chief Financial Officer
- G.M.  Naidu, Head of Operations & Manufacturing, CDMO & CMO
- Shrihari S. Mane, Chief Technology Officer

---
Source: rupiya.io/stocks/aartipharm
Disclaimer: For research and education only. Not investment advice.